Bartosz Hudzik/LinkedIn
Feb 11, 2026, 16:08
Bartosz Hudzik: Clinical Trials to Watch in 2026 – A Cardiovascular Lens
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn:
“Clinical trials to watch in 2026 — a cardiovascular lens
Nature Medicine highlights 11 trials poised to shape medicine in 2026. In cardiology, two stand out:
- Ziltivekimab – targeting the IL-6 inflammatory pathway to reduce residual inflammatory risk in atherosclerosis and CKD, moving beyond lipid-only prevention.
- Pelacarsen – a first-in-class antisense therapy for lipoprotein(a), tackling one of the most important genetically driven and previously untreatable CV risk factors.
Both are Phase 3 programs with the potential to redefine precision prevention.
2026 may be the year cardiovascular medicine shifts from risk markers to causal, target-specific therapies.”
More posts featuring Bartosz Hudzik on Hemostasis Today.
-
Jul 6, 2026, 22:54Louise St. Germain Bannon: I Wanted to Recognize the Incredible Staff Behind ISTH 2026
-
Jul 6, 2026, 21:46Armghan Ans: UPMC Washington Stroke Program Earns AHA Gold Plus Award for 16th Consecutive Year
-
Jul 6, 2026, 20:31Manik Madaan: Master Transfusion Reactions for USMLE In Less Than 60 Seconds
-
Jul 6, 2026, 19:25Ambreen Kashif: Highlighting the Impact of Temporary Donor Deferrals on Donor Retention
-
Jul 6, 2026, 19:23Rob Mac Sweeney: Anticoagulation Strategies for Cardiopulmonary Bypass in Heparin-Induced Thrombocytopenia
-
Jul 6, 2026, 19:22Nthabiseng Bapela: Interpreting INR in Patients on Warfarin – A Practical Clinical Framework
-
Jul 6, 2026, 19:20Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
-
Jul 6, 2026, 18:58Mostafa Faisal: High PNH Type II Neutrophil Proportions Are Associated With Thrombosis
-
Jul 6, 2026, 17:57When Hematocrit Exceeds 70 Percent: Challenges in Peripheral Blood Smear Evaluation and CBC Analysis – Seema Dawood